Tag: Research News
April 11 is World Parkinson’s Day.
At Shake It Up, we believe that when our community comes together, we can make a world of difference.
This ti...
National Parkinson’s Alliance formed to lead change for Parkinson’s community.
Shake It Up Australia is pleased to announce the formation of the N...
Shake It Up recently announced funding for a new research project investigating quantitative mapping of aSyn soluble and insoluble PTMs in selected br...
An international team of patient, research and industry leaders, including Shake It Up Australia, have collaborated to propose the first iteration of ...
Over 200,000 Australians are currently living with Parkinson’s disease, with a further 38 diagnosed everyday. It’s the fastest growing neu...
We are rapidly approaching the end of 2023, a huge year in Parkinson’s research. Thank you to everyone in our community for your steadfast support o...
Earlier this month, Shake It Up was thrilled to announce funding for year 2 of the Australian Parkinson’s Genetics Study, led by Associate Pro...
Earlier this month, Shake It Up was thrilled to announce funding for a new research project led by Nicolas Dzamko, PhD, Senior Research Fellow, Brain ...
Australia will soon have the capacity to host more in-depth and innovative clinical trials for Parkinson’s disease after funding was announced to de...
In this chat with Dr. Fazel Shabanpoor, we hear about his research into antisense oligonucleotides (ASOs), which offer a new therapeutic strategy in P...
In June this year, we shared the first of our regular quarterly progress updates for the Shake It Up Australia Foundation. Since then, we’ve seen ma...
In this chat with Dr. Cedric Bardy, Associate Professor at SAHMRI (South Australia Health and Medical Research Institute) and Flinders University, we ...
In this chat with Associate Professor Miguel RenterÃa, we hear about the Australian Parkinson’s Genetics Study, and how the study of genes is h...
Last month, Shake It Up CEO Vicki Miller and Founder Clyde Campbell had the privilege of travelling to Barcelona to attend the 2023 World Parkinson Co...
Content originally published on the UNSW website.
A new app, co-designed by people with Parkinson’s disease, has been launched to help those living ...
On the heels of a big breakthrough — a spinal fluid (CSF) test for Parkinson’s, or alpha-synuclein seed amplification assay (α-syn SAA in CSF) â€...
In December of last year, I took on the role as CEO of Shake It Up Australia, after nearly six years as Executive General Manager. At the time, I shar...
Scientists from UNSW Sydney with collaborators at Boston University have developed a tool that shows early promise in detecting the onset of Parkinson...
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced an enormous leap forward in the understanding of Parkinson’s disease w...
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative ...
WEHI (The Walter and Eliza Hall Institute of Medical Research), is establishing a Parkinson’s Disease Research Centre of Excellence in collaborative...
Parkinson’s disease (PD) currently affects over 10 million people worldwide, and 200,000 Australians live with the disease, while another 38 are...
A new research study being conducted by Abbvie aims to understand how Parkinson’s disease is affecting people living with the condition, their f...
Parkinson’s disease (PD) isn’t the same for every patient. Patients will progress at different rates, or experience certain symptoms that affect t...
The U.S. Food and Drug Administration (FDA) last week approved lecanemab (brand name Leqembi) developed by Eisai Co Ltd. and Biogen Inc. for people w...
Another new medication for Parkinson’s may soon be on its way to the U.S. Food and Drug Administration (FDA) for possible approval.
Neuroderm recent...
BRAIN-PENETRATING ANTISENSE OLIGONUCLEOTIDE TO DOWN-REGULATE ALPHA-SYNUCLEIN
Antisense oligonucleotides (ASOs) offer a new therapeutic strategy in Par...
At the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD), a research team funded by The Michael J. Fox Foundation is anno...
Researcher: Professor Paul Fisher
Research Institute: La Trobe University
Professor Fisher and his research team are investigating mitochondrial funct...
AÂ new study, funded by The Michael J. Fox Foundation, suggests that, among people with rheumatoid arthritis, use of the medications chloroquine and h...
Many people are curious how cannabis, including marijuana, may help Parkinson’s disease (PD) symptoms. While clinical trials have not yet proven saf...
A significant milestone in brain disease research was achieved early this week when the U.S. Food and Drug Administration (FDA) announced approval of...
People with Parkinson’s disease (PD) often ask about complementary medicine and alternative therapies that might work for different symptoms. Althou...
Study demonstrates the use of a wearable device in treatment of Parkinson’s disease resulted in significant improvement in patient outcomes compared...
New research published in the journal Brain suggests that people with diabetes who take the medication exenatide may have a lower risk of developing...
Star-shaped cells called astrocytes perform many duties in the brain, but their latest trick could replace dopamine cells lost in Parkinson’s diseas...
Last month Marco Baptista – Vice President of Research Programs for The Michael J. Fox Foundation joined more than 9,000 people from pharmaceuti...
A new study by Cedars-Sinai research suggests that if you were diagnosed with Parkinson’s before age 50, you might have been born with it.
The s...
A trial of great interest to the Parkinson’s community today reported top-line findings. The Nilotinib in Parkinson’s Disease (NILO-PD) study show...
Parkinson’s research continues to advance at a rapid pace. Led by moderator Soania Mathur, MD, co-chair of The Michael J. Fox Foundation’s Patient...
A recent study in the journal Neurology reports that impulse control disorders (ICDs) — compulsive gambling, shopping or eating, or excessive intere...
Millions of people reach for a caffeinated beverage each morning to jumpstart the day. Now, early research indicates that the stimulant that gets peop...
On October 30, more than 300 leaders in Parkinson’s disease (PD) research and business development gathered in NYC for The Michael J. Fox Foundation...
Lack of objective tests to diagnose Parkinson’s disease (PD) challenges drug development and patient care. While scientists are looking to pinpoint ...
At the current time, there is no identified biomarker for Parkinson’s disease (PD). In other words, there is no objective measure — no lab or imag...
A recently published study has revealed differences in gut bacteria in those with Parkinson’s disease based on their medications and geographic loca...
Sanofi Genzyme has started a clinical trial for a drug targeting cellular dysfunction seen in people with Parkinson’s disease (PD) and a GBA mutat...
New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson’s protein alpha-synuclein. To...
Researchers recently added to the list of Parkinson’s-associated genes when they identified mutations on TMEM230  linked to the disease. Discove...